Scope of the problem 6/2/2015
|
|
- Dorthy Wright
- 5 years ago
- Views:
Transcription
1 Interactive Case-Based Presentations and Audience Discussion Arthur Y. Kim, MD Assistant Professor of Medicine Harvard Medical School Director, Viral Hepatitis Clinic Massachusetts General Hospital Boston, Massachusetts Formatted: Chicago, IL: May 19,2015 Learning Objectives After attending this presentation, participants will be able to: Identify drug interactions between antiretrovirals and HCV agents Explain the rationale for antiviral treatment of HCV in HIV-infected individuals Apply recent advances in the treatment of HCV to HIV/HCV-coinfected individuals Slide 2 of 50 Scope of the problem Slide 3 of 50 HIV-1 and HCV share routes of transmission Worldwide burden: HIV 40 million Hepatitis C 180 million Co-infection is common, between 16-33% prevalence in HIVinfected persons Liver disease (largely due to HCV) is 2nd leading cause of death if HIV+ 1
2 A tale of two viruses Slide 4 of 50 Sex > Blood HIV Targets immune cells Years to clinical illness High levels of viremia 10^9 particles/day Low fidelity of reverse transcriptase (RNA-DNA) Frequently mutates 1 cure after BMT Blood > Sex HCV Targets hepatocytes Decades to clinical illness High levels of viremia 10^12 particles/day Low fidelity of RNA-RNA polymerase Frequently mutates >90% Curable Case Slide 5 of 50 Infected via husband who died of AIDS-related complications Insulin-dependent diabetes developed 5 years earlier Hypertension: metoprolol, lisinopril, amlodipine PCOS: ethinyl estradiol / progestin Other meds: ASA 81 mg BMI: 31, no significant EtOH use HIV: Suppressed on TDF/FTC + ritonavir + atazanavir HCV: 1b infection, 12 years ago, bx 1/6 fibrosis, attempted PEG-IFN /, complicated by anemia, requiring transfusion, managed by dose reduction + erythropoeitin Case Slide 6 of 50 Prior HIV regimens: AZT/3TC, AZT/3TC/indinavir, TDF/FTC/EFV, now suppressed on TDF/FTC + ritonavir + atazanavir HCV: 1b infection, 12 years ago biopsy 1/6 fibrosis Laboratory ALT AST TBili 63 U/L 71 U/L 2.2 mg/dl INR 1.1 Platelets 152,000 egfr 62 ml/min/1.73m 2 What would inform a decision to treat? 2
3 Slide 8 of 50 How do you decide to (re-)stage the degree of liver fibrosis for this patient? 1. No further staging - labs sufficient 2. Routine ultrasound 3. FibroTest 4. Transient elastography 5. MR elastography 6. Liver biopsy 7. Other 13% 33% 8% 21% 17% 8% 0% HIV / HCV co-infection is double trouble Slide 9 of 50 Compared to HIV-negative individuals, those with HIV suffer from: 1. Higher rates of persistence (lower rates of spontaneous clearance) 2. Accelerated rate of fibrosis, higher rates of cirrhosis 3. Higher rates of decompensation & higher liverrelated mortality Slide 10 of 50 HIV still associated with higher rates of HCVrelated fibrosis progression HIV+HCV HCV Kirk et al. Ann Intern Med 2013; 158:
4 HIV associated with higher rates of HCV-related liver decompensation, even when on ART Slide 11 of 50 Lo Re V et al. Annals of Internal Medicine 2014 Challenge of HIV/HCV Coinfection: Higher rates of decompensation & higher liver-related mortality Slide 12 of 50 Opportunity to treat with antivirals and achieve cure AASLD/IDSA/IAS-USA HCV Guidance A perfect storm for sexual HCV transmission: HIV+MSM Slide 13 of 50 Bloody practices Semen exposure Other STDs Sex Drugs Crystal methamphentamine Sildenafil Internet HIV Higher levels of virus in plasma and semen Immune deficiency, especially at GI mucosa 4
5 Slide 14 of 50 Case Slide 15 of 50 HIV: Suppressed on TDF/FTC + ritonavir + atazanavir HCV: 1b infection, 12 years ago, bx 1/6 fibrosis, attempted PEG-IFN /, complicated by anemia, requiring transfusion, managed by dose reduction + erythropoeitin, stopped after 6 months for futility Fibrosure- confounded Ultrasound - mild splenomegaly, present x 10 years Transient elastography - 15 kpa Slide 16 of 50 Possible Combinations of HCV treatments Genotypes PEG IFN GT3 10% GT4 4% BOC GT2 9% TLV SMV GS 9451 PTV/r ASV MK 5172 LDV GS 9669 DCV BMS MK 8742 GT1 77% 5
6 SVR Rate SVR12 (ITT) SVR12 (ITT) 6/2/2015 Slide 18 of 50 What would be your choice of antiviral treatment? 1. Simeprevir + sofosbuvir x 24w 2. Simeprevir + sofosbuvir + x 24w 3. Ledipasvir / sofosbuvir FDC x 12w 4. Ledipasvir / sofosbuvir FDC + x 12w 5. Ledipasvir / sofosbuvir FDC x 24w 6. Paritaprevir/r/ombitasvir FDC + dasabuvir x 12w 7. Paritaprevir/r/ombitasvir FDC + dasabuvir + x 12w 8. Paritaprevir/r/ombitasvir FDC + dasabuvir x 24w 63% 5% 26% 5% 0% 0% 0% 0% PEG BOC 67 Slide 19 of 50 HCV versus HIV/HCV, genotype 1 in Clinical Trials Not head to head comparison 63 PEG 75 TLV PEG SMV PEG /521 42/53 40/64 28/38 206/260 13/15 15/23 7/10 9/17 16/28 260/292 17/19 17/25 87/114 0 BOC TLV SMV (Naive) SMV SMV (Partial) SMV (Null) P/R/x12 /Rx24w (Relapser) Poordad F et al, NEJM 2011; 364: vs. Sulkowski et al. Lancet Infect Dis 2013; 13(7): Jacobson I et al, NEJM 2011; 364: vs. Sulkowski et al. Ann Intern Med 2013; 159(2): Antiviral Drugs Advisory Committee Meeting, FDA review, 10/24/13 HCV HIV/HCV C208, C216, C206, C212, HPC3007, Dieterich et al. Clin Infect Disease 2014 (epub ahead of print) Lawitz et al. NEJM 2013 versus Torres-Rodriguez et al., IDSA 2013 Osinusi et al., JAMA 2013;310(8): versus Sulkowski et al. JAMA 2014;312(4): Slide 20 of 50 PEARL-III and IV, 12 week 3D Regimens for GT1 4.8% African- American, ~10% F % African- American, ~18% F / /210 Naive 1b noncirrhotics 3D x12w 3D + x12w 0 Naive 1a noncirrhotics Ferenci et al. NEJM
7 SVR 12 6/2/2015 Regimens in Phase 3 for GT1 Slide 21 of LDV LDV ION-1 and 2: addition did not enhance SVR Cirrhotics (TURQUOISE) 24 weeks 95.9% SVR / / / / / /215 SAPPHIRE-I SAPPHIRE-II TURQUOISE-II ION-1 ION-2 ION-3 Tx-Exp (ION-2) 24 wks LDV/ 108/109 SVR FDA filings LDV/ 2/10/14 3D 4/22/14 no cirrhosis naive no cirrhosis 100% cirrhosis 16% cirrhosis null responder 55% naive 20% cirrhosis Tx-Exp no cirrhosis naive SAPPHIRE-1 Feld et al. NEJM 2014, SAPPHIRE-2 Zeuzem et al. NEJM 2014, ION-1 Afdhal et al. NEJM 4/12/2014, ION-2 Afdhal et al. NEJM 2014; 370(16):1483, ION-3 Kowdley et al. NEJM 4/12/2014. SAPPHIRE/TURQUOISE are 12 week arms only. ION studies are -sparing arms only Event Slide 22 of 50 Adverse Events 3D regimen 12 weeks in SAPPHIRE-1 3D + x 12 weeks (n=473) Placebo (n=217) Discontinuation due to AE 3 (0.6%) 0 Serious AE 10 (2.1%)* Fatigue 164 (34.7%) 45 (28.5%) Headache 156 (33.0%) 42 (26.6%) Nausea 112 (23.7%) 21 (13.3%) Insomnia 66 (14.0%) 12 (7.6%) Asthenia 57 (12.1%) 6 (3.8%) Diarrhea 65 (13.7%) 11 (7.0%) Rash 51 (10.8%) 9 (5.7%) Pruritus 80 (16.9%) 6 (3.8%) Anemia 27 (5.8%)** * 2 were possibly related to 3D by investigator Feld et al. NEJM 2014; Epub ahead of print **no cases of anemia < 8.0 g/dl Slide 23 of 50 Adverse Events LDV/ 12 weeks in ION-1 Event LDV/ x 12 weeks (n=214) LDV LDV+ x 12 weeks (n=217) Discontinuation due to AE 0 0 Serious AE 1 (<1%) 7 (3%) Fatigue 44 (21%) 79 (36%) Headache 53 (25%) 49 (23%) Nausea 24 (11%) 37 (17%) Insomnia 17 (8%) 45 (21%) Asthenia 14 (7%) 23 (11%) Diarrhea 24 (11%) 37 (17%) Rash 16 (7%) 21 (10%) Irritability 11 (5%) 17 (8%) Cough 6 (3%) 21 (10%) Pruritus 11 (5%) 22 (10%) Anemia 0 25 (12%) Afdhal et al. NEJM 2014; Epub ahead of print 7
8 SVR 12 6/2/2015 Extension of therapy beyond 12 weeks may be necessary for GT1a, null responder, cirrhotic Slide 24 of weeks 24 weeks TURQUOISE II 100% cirrhosis /64 14/15 13/13 52/56 11/11 10/10 40/50 39/42 Naive Partial Null Relapse Poordad et al. TURQUOISE - II, EASL 2014 Slide 25 of 50 What would you choose for 1a infection? Non-cirrhotic Cirrhotic Naïve /LDV x 12 weeks /LDV x 12 weeks 3D + x 12 weeks 3D + x 24 weeks SMV/ +/- x 12 weeks SMV/ +/- x 24 weeks Experienced /LDV x 12 weeks /LDV x 24 weeks /LDV+ x 12 weeks 3D + x 12 weeks 3D + x 24 weeks SMV/ +/- x 12 weeks SMV/+/- x 24 weeks Slide 26 of 50 What would you choose for 1b infection? Non-cirrhotic Cirrhotic Naïve /LDV x 12 weeks /LDV x 12 weeks 3D x 12 weeks SMV/ x 12 weeks 3D + x 12 weeks SMV/ x 24 weeks Experienced /LDV x 12 weeks /LDV x 24 weeks /LDV+ x 12 weeks 3D x 12 weeks 3D+ x 12 weeks SMV/+/- x 12 weeks SMV/+/- x 24 weeks 8
9 Slide 28 of 50 Which of these is most problematic with SMV 1. Insulin 2. Metoprolol 3. Lisinopril 4. Amlodipine 5. Ethinyl estradiol / progestin 6. ASA 81 mg 7. TDF/FTC 8. Ritonavir + Atazanavir 78% 17% 6% 0% 0% 0% 0% 0% Slide 29 of 50 Drug-interactions with SMV/ SMV Sofosbuvir Substrate of P-gp and BCRP; potent P-gp inducers may decrease sofosbuvir concentrations Tipranavir, rifampin, St. John s wort induces P-gp at steady state Do not use with amiodarone Simeprevir Mild inhibitor of CYP1A2 and intestinal CYP3A4, inhibits OATP1B1/3 and P-gp Protein bound, biliary elimination Multiple drug interactions (usually a victim, not a perpetrator) From guidelines: Simeprevir should NOT be used with efavirenz, etravirine, nevirapine, cobicistat, or any HIV protease inhibitors. Slide 31 of 50 Which of these is most problematic with 1. Insulin 2. Metoprolol 3. Lisinopril 4. Amlodipine 5. Ethinyl estradiol / progestin 6. ASA 81 mg 7. TDF/FTC 8. Ritonavir + Atazanavir 0% 0% 0% 6% 17% 0% 11% 67%
10 Slide 33 of 50 Which of these is most problematic with 1. Insulin 2. Metoprolol 3. Lisinopril 4. Amlodipine - levels rise, may need dose reduction 5. Ethinyl estradiol / progestin - elevated LFTs - avoid 6. ASA 81 mg 7. TDF/FTC 8. Ritonavir + Atazanavir - elevated bilirubin % 0% 0% 0% 0% 0% 0% 0% Slide 34 of 50 Turquoise-1: 3D regimen for HIV/HCV-coinfected patients, GT1 n=63 Sulkowski et al. JAMA 2015 Slide 35 of 50 Turquoise-1: 3D regimen for HIV/HCV-coinfected patients, GT1 n=63 Sulkowski et al. JAMA
11 % of patients 6/2/2015 TURQUOISE-1 3D+ x 12 or 24 wks in HIV/HCV SVR 12: Treatment naive + PR experienced Slide 36 of ITT virologic response rates wks 24-wks Mean age 58 ~24% Black 19% cirrhosis n=63 r/atv (n=28) RAL (n=35) No discontinuations 1 withdrew consent 1 breakthrough in nonresponder/cirrhotic 5 >moderate AEs 0 31/31 32/32 30/31 31/32 29/31 31/32 29/31 RVR EOTR SVR4 SVR12 High CD4 (median 600s) 5 had blips HIV-1 RNA > 40 copies/ml, all re-suppressed without change or intensification A5329 opening shortly includes RAL and r/drv (QD -> BID) Sulkowski et al. JAMA D Regimen for HIV/HCV coinfection compatable with HIV protease inhibitors? Slide 37 of 50 PTV/r DRV Ctrough lower ATV Ctrough higher LPV Ctrough higher ABT-450 levels higher with r/atv QPM and r/lpv & levels relatively unaffected Well tolerated, no new safety concerns 207/ /210 Khatri et al. ICAAC September 2014, Washington DC Abstract #038 Recommended no dose adjustment of 3D. Due to higher RTV dose, avoid with r/lpv Slide 38 of 50 Turquoise-1: 3D regimen for HIV/HCV-coinfected patients, GT1 n=63 Eron et al. ICAAC September 2014, Washington DC Abstract #673 11
12 Slide 40 of 50 Which of these is most problematic with 1. Insulin 2. Metoprolol 3. Lisinopril 4. Amlodipine 5. Ethinyl estradiol / progestin 6. ASA 81 mg 7. TDF/FTC 8. Ritonavir + Atazanavir 15% 15% 30% 40% 0% 0% 0% 0% Tenofovir Exposures Slide 41 of 50 NNRTIs Without With LDV/ 1,2 LDV/ 3 RTV-Boosted PIs Without With LDV/ 4-9 LDV/ 10 Range of TFV exposures with available safety data EFV RPV ATR CPA FPV SQV LPV/r ATV DRV ATV DRV * N = * 24 TFV exposures are higher when TDF is coadministered with LDV/ compared to without LDV/ Compared to the range of TFV exposures with available safety data For EFV or RPV: TFV exposures fall within the range 1 For RTV-boosted PIs: TFV exposures partially exceed the range 2 1, Data on File, Gilead Sciences. 2. Hoetelmans RMW, et al. 6 th IWCPHT Quebec City, Canada. Poster # German P, et al. ICPHHT #O6 4. Luber AD, et al. HIV Medicine. 2010;11:193-9 (FPV+RTV) 5. Chittick GE, et al. AAC. 2006; 50(4): (SQV+RTV) 6. Zhu. 9th IWCPHT #023 (ATV+RTV & LPV/r ) * HIV-infected subjects in CASTLE study 7. Kearney B, et al. JAIDS. 2006;43(3): (LPV/r) 10. German P, et al. CROI Agarwala S, et al. 6th IWCPHT #16. (ATV+RTV) 9.. Hoetelmans RMW, et al. BJCP. 2007;64(5): (DRV+RTV) Slide Courtesy of Gilead Sciences LDV/ ERADICATE: Changes in Renal Function Slide 42 of 50 12
13 ledipasvir + sofosbuvir (FDC) ION-4 for HIV/HCV Slide 43 of 50 Wk 0 Wk 12 Wk 24 N=335 LDV LDV/ SVR12 LDV Phase 3, multicenter, open-label study (NCT ) HCV GT 1 or 4 patients in US, Canada, and New Zealand Broad inclusion criteria HCV treatment-naïve or treatment-experienced 20% with compensated cirrhosis Platelets 50,000/mm 3 ; hemoglobin 10 mg/dl, CrCl 60 ml/min HIV-1 positive, HIV RNA <50 copies/ml; CD4 cell count >100 cells/mm 3 ART regimens included emtricitabine and tenofovir disoproxil fumarate plus efavirenz, raltegravir, or rilpivirine Naggie et al. CROI 2015 ledipasvir + sofosbuvir (FDC) ION-4 for HIV/HCV Slide 44 of 50 LDV Naggie et al. CROI 2015 ledipasvir + sofosbuvir (FDC) ION-4 for HIV/HCV Slide 45 of 50 LDV Naggie et al. CROI
14 ledipasvir + sofosbuvir (FDC) ION-4 for HIV/HCV Slide 46 of 50 LDV Naggie et al. CROI 2015 Slide 48 of 50 HIV: TDF/FTC + ritonavir + atazanavir HCV: 1b infection, 12 years ago, bx 1/6 fibrosis, nonresponder, Fibroscan - 15kPa For antiretroviral LDV/, what would you do? 1. Continue regimen, switch if renal monitoring shows change 2. Reduce dose of tenofovir 3. Swap tenofovir for abacavir 4. Swap ritonavir/atazanavir for raltegravir 5. Both 2 and 3 6. Something else 28% 8% 4% 36% 12% 12% HCV Interactions Summary Slide 49 of 50 LDV LDV/: Key interactions - monitor for potential tenofovir toxicity Particularly with HIV protease inhibitors Care with egfr < 60 ml/min/1.73 m 2, high-risk patients Monitor urine protein, serum BUN/Cr, electrolytes including phosphorus PTV/r 3D regimen: Key interactions - AVOID with efavirenz, rilpivirine, lopinavir/ritonavir Ensure proper ritonavir dosing ACTG 5329 will examine compatibility with boosted darunavir 14
15 Identifying and Managing Interactions (Jen Kiser) Slide 50 of 50 Kiser JJ, Burton JR, Jr, Everson GT. Nature Reviews Gastroenterol Hepatol 2013;10: HCV Drug-Drug Interactions Slide 51 of 50 Requires close attention - develop a systematic approach HIV antiretrovirals Do NOT interrupt therapy Determine need and feasibility for ART switch Factors include prior genotypic testing and ARV history Consult HIV specialist With present cautions and contraindications, majority of patients may require consideration of ARV change 1 HIV suppression remains goal, without compromising future options Monitor adherence, side effects closely during switch Slide 52 of 50 ARV Interaction Score Card Kisergram Simeprevir 1 Sofosbuvir 2 Ledipasvir 3-5 Daclatasvir 6,7 3D 8-10 ATV/r No data No data LDV, ATV a DCV b ABT450 ; ATV DRV/r SIM ; DRV ; DRV LDV, DRV a DCV 3D / ; DRV LPV/r No data No data No data DCV ABT450 ; LPV TPV/r No data No data No data No data No data EFV SIM ; EFV ; EFV LDV ; EFV a DCV b No PK data c RPV SIM ; RPV ; RPV LDV ; RPV No data ABT450 ; RPV ETR No data No data No data No data No data RAL SIM ; RAL ; RAL LDV ; RAL No data 3D ; RAL EVG/cobi No data ; ELV/cobi LDV ; ELV/cobi No data No data DTG No data No data No data No data No data MVC No data No data No data No data No data TDF SIM ; TFV ; TFV LDV ; TFV DCV ; TFV 3D ; TFV a Watch renal function, TFV levels increased, b Decrease DCV dose to 30mg QD with ATV, increase DCV dose to 90mg QD with EFV, c 3D + EFV led to premature study discontinuation due to toxicities 1 Ouwerkerk-Mahadaven S IDWeek 2012, 2 Kirby B AASLD 2012, 3 Harvoni package insert, 4 German P 15 th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy 2014, 5 German P, CROI 2015, 6 Bifano M, et al. Antivir Ther. 2013;18(7):931-40, 7 Eley T HIVDART 2014, 8 Khatri ICAAC 2014, 9 Khatri ICAAC 2014, 10 Viekira Pak package insert Slide Courtesy of J Kiser 15
16 Case Slide 53 of 50 HIV: TDF/FTC + ritonavir + atazanavir HCV: 1b infection, 12 years ago, bx 1/6 fibrosis, nonresponder, Transient elastography - 15kPa Endoscopy negative for varices egfr = 62 - changed TDF -> abacavir after B*5701 Insurance preference paritaprevir/r/ombitasvir/dasabuvir Changed r/atv -> raltegravir Treatment of HCV Slide 54 of 50 Slide 55 of 50 16
17 Interactive Case-Based Presentations and Audience Discussion Arthur Y. Kim, MD Assistant Professor of Medicine Harvard Medical School Director, Viral Hepatitis Clinic Massachusetts General Hospital Boston, Massachusetts Formatted: Chicago, IL: May 19,
6/2/2015. Interactive Case-Based Presentations and Audience Discussion
Interactive Case-Based Presentations and Audience Discussion Arthur Y. Kim, MD Assistant Professor of Medicine Harvard Medical School Director, Viral Hepatitis Clinic Massachusetts General Hospital Boston,
More informationTreatment of HCV in HIV/HCV Coinfection
Treatment of HCV in HIV/HCV Coinfection Michael S. Saag, MD Associate Dean, Global Health Professor of Medicine Director, Center for AIDS Research University of Alabama at Birmingham Birmingham, Alabama
More informationCan we afford to Cure all HIV-HCV Co-infected Patients of HCV?
Can we afford to Cure all HIV-HCV Co-infected Patients of HCV? Michael S. Saag, MD Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama FINAL AU EDITED: 09-17-14 Disclosure Dr
More informationHIV/HCV Co-Infection
HIV/HCV Co-Infection 2015 Kentucky Conference on Viral Hepatitis Matt Cave, M.D. Associate Professor Department of Medicine Division of Gastroenterology, Hepatology, & Nutrition Department of Pharmacology
More informationHIV-HCV coinfection. Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland
HIV-HCV coinfection Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland Disclosures Principal investigator for research grants Funds paid to Johns Hopkins
More informationUpdate on Drug Interactions of HIV/HCV Treatment Regimens Jennifer J. Kiser, PharmD
Update on Drug Interactions of HIV/HCV Treatment Regimens Jennifer J. Kiser, PharmD Associate Professor University of Colorado Disclosures Dr. Kiser receives research funding (paid to her institution)
More information4/30/2015. Interactive Case-Based Presentations and Audience Discussion. Debika Bhattacharya, MD, MSc. Learning Objectives
4/3/215 Interactive Case-Based Presentations and Audience Discussion Debika Bhattacharya, MD, MSc Assistant Clinical Professor University of California Los Angeles Los Angeles, California Formatted:4-27-215
More informationPotential Issues in Treating HIV/HCV co-infection with new HCV antivirals
State of the Art in Hepatitis C Virus Infection in HIV/HCV-Coinfected Patients FORMATTED: 11/17/15 David L. Wyles, MD Associate Professor of Medicine University of California San Diego San Diego, California
More informationAntiviral treatment in Unique Populations
Antiviral treatment in Unique Populations Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Unique HCV Populations HIV/HCV co-infected
More informationInitial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona
Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives
More informationCurrent Management of Hepatitis C Virus Infection
Current Management of Hepatitis C Virus Infection Kristen M. Marks, MD Assistant Professor Weill Cornell Medicine New York, New York FORMATTED: 10/13/16 Financial Relationships With Commercial Entities
More informationIFN-free for Genotype 1 HCV: the current landscape. Prof. Graham R Foster
IFN-free for Genotype 1 HCV: the current landscape Prof. Graham R Foster Wonderful new drugs are coming Poordad F, et al. New Engl J Med 2014; online DOI: 10.1056/NEJMoa1402869. 2 The New Drugs Two treatment
More informationCase 2: Coinfection. Patient Case
Case 2: Coinfection Jennifer J. Kiser, PharmD Assistant Professor University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Aurora, Colorado FORMATTED: 04-21-14 Learning Objectives After
More information5/2/2016. Andrew I. Aronsohn, MD Associate Professor of Medicine University of Chicago Chicago, Illinois. Learning Objectives
Challenges in the Management and Treatment of HIV/Hepatitis C Virus Coinfection Andrew I. Aronsohn, MD Associate Professor of Medicine University of Chicago Chicago, Illinois FORMATTED: 05/02/2016 Chicago,
More informationPivotal New England Journal of Medicine papers 2014 Phase 3 Trial data
4 th HCV Therapy Advances Meeting Paris, December 12-13, 14 Pivotal New England Journal of Medicine papers 14 Phase 3 Trial data Stefan Zeuzem, MD University of Frankfurt Germany Disclosures Consultancies:
More informationEvolution of Therapy in HCV
Hepatitis C: Update on New Therapies and AASLD 13 David Bernstein, MD, FACP, AGAF, FACP Professor of Medicine Hofstra North Shore-LIJ School of Medicine Evolution of Therapy in HCV 199 1999 1 13 (%) SVR
More informationLearning Objective. After completing this educational activity, participants should be able to:
Learning Objective After completing this educational activity, participants should be able to: Use patient characteristics and preferences to select HCV treatment strategies that maximize the potential
More information6/2/2015. Interactive Case-Based Presentations and Audience Discussion
6/2/215 Interactive Case-Based Presentations and Audience Discussion Andrew Aronsohn, MD Assistant Professor of Medicine University of Chicago Medical Center Chicago, Illinois Formatted:5-6-215 Washington,
More informationLedipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationTough Cases in HIV/HCV Coinfection
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Tough Cases in HIV/HCV Coinfection John Scott, MD, MSc Assistant Professor University of Washington Presentation prepared by: J Scott Last Updated: Jun 5, 2014
More information3/28/2016. The Top 5 Things to Remember about Treating HCV
The Top 5 Things to Remember about Treating HCV Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University School of Medicine Durham, North Carolina FORMATTED: MM/DD/YY New York, New York:
More informationSlide Presentation. Management of HCV Coinfection Susanna Naggie, MD, MHS
Slide Presentation Management of HCV Coinfection Assistant Professor of Medicine Duke University School of Medicine & Durham VA Medical Center Director of Infectious Diseases Duke Clinical Research Institute
More informationHIV/HCV Coinfection: Why It Matters and What To Do About It. Cody A. Chastain, MD 10/26/16
HIV/HCV Coinfection: Why It Matters and What To Do About It Cody A. Chastain, MD 10/26/16 Disclosures I have no relevant financial disclosures. Objectives At the end of this lecture, the learner will be
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More informationCan a One-Size-Fits-All Approach Be Applied to All Treatment-Naïve GT1 HCV Patients?
Can a One-Size-Fits-All Approach Be Applied to All Treatment-Naïve GT1 HCV Patients? Ira M. Jacobson, MD Vincent Astor Distinguished Professor of Medicine Chief, Division of Gastroenterology and Hepatology
More informationVII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES
VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES REGIMENES TERAPÊUTICOS DE LA HEPATITIS C, INTERFERÓN FREE A Coruña 2 Febrero 2013 Rui Sarmento e Castro Centro Hospitalar do Porto HJU ECS Universidade
More informationInitial Treatment of the Hepatitis C Virus-Infected Patient
IDSA/AASLD www.hcvguidelines.org http://www.easl.eu/research/our-contributions/clinical-practice-guidelines/detail/easl-recommendations-ontreatment-of-hepatitis-c-216 Initial Treatment of the Hepatitis
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationRome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING
Rome, February 20-21 nd 2014 Riunione Annuale AISF 2014 14 th AISF ANNUAL MEETING Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations IFN
More informationMy HCV patient is co-infected with HIV: how to manage?
EASL «White Nights of Hepatology 2016» My HCV patient is co-infected with HIV: how to manage? A.V. Кravchenko MD, Professor Russia AIDS Federal Center Central Research Institute of Epidemiology St.-Petersburg,
More informationHepatitis C Virus Management
Hepatitis C Virus Management FORMATTED: 04/20/17 New York, New York: February 24, 2017 Marion G. Peters, MD John V. Carbone, Endowed Chair Professor of Medicine University of California San Francisco San
More informationSeparate clinical trials for HIV- HCV coinfected patients are NOT a necessity. Patrick Ingiliz, Berlin
Separate clinical trials for HIV- HCV coinfected patients are NOT a necessity Patrick Ingiliz, Berlin Back in the days when HCV genotype 1 was the problem SVR (%) 100 90 80 70 60 50 40 30 20 10 0 35% PRESCO
More informationNew Antivirals for Hep C in Context of HIV: Vosevi and Mavyret
New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret John Scott, MD, MSc, FIDSA November 16, 2017 This presentation is intended for educational use only and does not in any way constitute medical
More informationICVH 2016 Oral Presentation: 28
Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients A Luetkemeyer 1, C Cooper 2, P Kwo 3, K
More informationAri Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College
Ari Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College New York State Law Goes into Effect January 1, 2014 Hepatitis C Virus
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data
More information8/5/2014. A new era of HCV clinical management. Direct-Acting Antivirals for Hepatitis C. Goal of HCV treatment is viral cure HIV HBV HCV
NS5B NS5B 8/5/214 A new era of HCV clinical management Mark Sulkowski, MD Professor of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Disease and Gastroenterology/Hepatology
More informationSHOULD EVERYONE WITH HCV/HIV COINFECTION BE TREATED NOW?
SHOULD EVERYONE WITH HCV/HIV COINFECTION BE TREATED NOW? Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Disclosures
More informationGlobal Prevalence of HBV, HCV, HIV
Treatment of Patients with HCV and HIV Paul Y. Kwo, MD, FACG Professor of Medicine Stanford University email: pkwo@stanford.edu Global Prevalence of HBV, HCV, HIV 24 m Journal of Clinical Virology Page
More informationHCV Treatment of Genotype 1: Now and in the Future
HCV Treatment of Genotype 1: Now and in the Future Bruce R. Bacon, MD, FACG James F. King, MD Endowed Chair in Gastroenterology Professor of Internal Medicine Co-Director of the Abdominal Transplant Program
More informationAASLD/IDSA HCV treatment guidelines. Arthur Y. Kim, MD Massachusetts General Hospital Harvard Medical School
AASLD/IDSA HCV treatment guidelines Arthur Y. Kim, MD Massachusetts General Hospital Harvard Medical School Disclosure Statement for Arthur Kim Grant/research support to institution, last 12 months: Gilead
More informationHepatitis C Genotypes
9/2/21 OBJECTIVES Project ECHO HCV Collaborative HCV in 21: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College
More informationUpdate in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana
More informationOmbitasvir-Paritaprevir-Ritonavir + Dasabuvir (Viekira Pak)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ombitasvir-Paritaprevir-Ritonavir + Dasabuvir (Viekira Pak) Prepared by: Sophie Woolston, MD and David H. Spach, MD Last Updated: December 29, 2014 OMBITASVIR-PARITAPREVIR-RITONAVIR
More informationHepatitis C Treatment 2014
Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype
More information6/2/2015. Interactive Case-Based Presentations and Audience Discussion
Interactive Case-Based Presentations and Audience Discussion Charles W. Flexner, MD Professor of Medicine, Pharmacology, and International Health The Johns Hopkins University Baltimore, Maryland Formatted:05-05-2015
More informationHCV in 2017: New Therapies and New Opportunities. Presentation prepared by: Date prepared: OBJECTIVES
Project ECHO HCV Collaborative HCV in 217: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College of Pharmacy University
More informationCARE FOR PATIENTS WITH CHRONIC HCV/HIV COINFECTIONS
CARE FOR PATIENTS WITH CHRONIC HCV/HIV COINFECTIONS JOHN I. MCNEIL, MD, FACP MAXIMED ASSOCIATES MARYLAND JUNE 8, 2017 CME Disclosures: Planning Committee And Speaker Speaker: The following speaker has
More informationDirect Acting Antivirals for the Treatment of Hepatitis C Infection
Hepatitis C Core Curriculum, Module 2 Direct Acting Antivirals for the Treatment of Hepatitis C Infection Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Objectives Discuss the evolution of hepatitis C treatment
More informationHCV/HIV Coinfection ANTON AND MARGARET FUISZ CHAIR IN MEDICINE. HIV and HCV Share Risk Factors PREVALENCE OF CO-INFECTION BY RISK FACTOR 60%
HCV/HIV Coinfection BRUCE A. LUXON, MD, PHD, FACG ANTON AND MARGARET FUISZ CHAIR IN MEDICINE PROFESSOR AND CHAIRMAN DEPARTMENT OF MEDICINE GEORGETOWN UNIVERSITY HIV and HCV Share Risk Factors PREVALENCE
More informationLatest Treatment Updates for GT 2 and GT 3 Patients
Latest Treatment Updates for GT 2 and GT 3 Patients Eric Lawitz, MD, AGAF, CPI Vice President, Scientific and Research Development The Texas Liver Institute Clinical Professor of Medicine University of
More informationWhat is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago
What is the Optimized Treatment Duration? To Overtreat versus Undertreat Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives: 1. Discuss patient populations appropriate
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were
More informationSlide 1 Will DAA drug interactions matter in the future? David Back. David Back University of Liverpool UK. University of Liverpool June 2015
Slide 1 Will DAA drug interactions matter in the future? David Back University of Liverpool UK David Back University of Liverpool June 2015 Disclosures Honoraria received for Advisory Boards, lectures
More informationHepatitis C Virus: HIV/Hepatitis C Coinfection Wednesday, August 24, 2016
Hepatitis C Virus: HIV/Hepatitis C Coinfection Debika Bhattacharya, MD, MSc Associate Clinical Professor University of California Los Angeles Los Angeles, California Washington, DC: August 24, 2016 Slide
More informationTreating Hepatitis C-HIV Coinfected Patients Welcome to the Real World
Treating Hepatitis C-HIV Coinfected Patients Welcome to the Real World H. Nina Kim, MD MSc Associate Professor of Medicine University of Washington Division of Allergy & Infectious Diseases April 21, 2017
More informationClinical Pharmacology of DAA s for HCV: What s New & What s In Pipeline
Clinical Pharmacology of DAA s for HCV: What s New & What s In Pipeline Kirk Bertelsen, PhD Clinical Pharmacology Janssen Pharmaceuticals, Research & Development 4/24/2013 1 Incivo Simeprevir 2 Janssen
More informationManagement of HIV/HCV Coinfection. Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY
Management of HIV/HCV Coinfection Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY Disclosure Dr. Marks has received grants and research support from Gilead Sciences
More informationEASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor
More informationReal World Management of HCV in HIV: Approach to Initial Therapy with focus on new DAAs
Real World Management of HCV in HIV: Approach to Initial Therapy with focus on new DAAs Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, New York Financial Relationships
More informationHepatitis C Medications Prior Authorization Criteria
Hepatitis C Medications Authorization Criteria Epclusa (/velpatasvir), Harvoni (ledipasvir/), Sovaldi (), Daklinza (daclatasvir), Zepatier (elbasvir/grazoprevir), Olysio (simeprevir), Viekira Pak (ombitasvir/paritaprevir/ritonavir;
More information2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients
2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director
More informationHepatitis C in HIV Coinfection. Annie Luetkemeyer, MD Division of HIV, ID and Global Medicine ZSFG, UCSF
Hepatitis C in HIV Coinfection Annie Luetkemeyer, MD Division of HIV, ID and Global Medicine ZSFG, UCSF Disclosures I have received research grant support to UCSF related to HCV from the following: Abbvie
More informationHEPATITIS C. Mitchell L. Shiffman, MD, FACG Director. Liver Institute of Virginia. Richmond and Newport News, VA
NEW TREATMENTS FOR HEPATITIS C Mitchell L. Shiffman, MD, FACG Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA Liver Institute of Virginia Education, Research
More informationSelecting HCV Treatment
Selecting HCV Treatment Caveats Focus on treatment selection for genotypes 1, 2, and 3. Majority of US population infected with GT 1, 2, or 3 GT 4 treatment closely reflects GT 1 treatment GT 5 and 6 are
More informationThe HCV Pipeline Ira M. Jacobson, MD, FACP, FACG, AGAF. Slide Presentation. IFN-free DAA combinations (G1)
Slide Presentation The HCV Pipeline Vincent Astor Distinguished Professor of Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the Study of Hepatitis C Weill Cornell
More informationTreatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona
Treatement Experienced patients without cirrhosis Rafael Esteban Hospital Universitario Valle Hebron Barcelona Agenda With IFN PegIFN+ Ribavirin + Simeprevir PegIFN+ Ribavirin+ Sofosbuvir Without IFN Sofosbuvir
More informationTreatment of chronic hepatitis C in HIV co-infected patients
Treatment of chronic hepatitis C in HIV co-infected patients Vicente Soriano Department of Infectious Diseases Hospital Carlos III, Madrid, Spain The most prevalent chronic viral infections in humans HBV
More informationEliminating Hepatitis C from New Zealand
Eliminating Hepatitis C from New Zealand Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital Disclosures I have the following
More informationHIV-HCV Co-Infection in Shobha Swaminathan, MD Associate Professor of Medicine Rutgers New Jersey Medical School
HIV-HCV Co-Infection in 2018 Shobha Swaminathan, MD Associate Professor of Medicine Rutgers New Jersey Medical School AASLD/IDSA and DHHS Guidance: HIV/HCV Coinfection All pts with HIV should be screened
More informationHCV Treatment in 2016: Genotypes 1, 2, and 3. Cody A. Chastain, MD October 12, 2016
HCV Treatment in 2016: Genotypes 1, 2, and 3 Cody A. Chastain, MD October 12, 2016 Disclosures I have no financial disclosures. Caveats I will only discuss treatment of GT 1-3. Majority of US population
More informationDr Janice Main Imperial College Healthcare NHS Trust, London
BHIVA AUTUMN CONFERENCE 2014 Including CHIA Parallel Sessions Dr Janice Main Imperial College Healthcare NHS Trust, London 9-10 October 2014, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationHepatitis C in HIV Women: Pardigm Shift with all oral Therapies
Hepatitis C in HIV Women: Pardigm Shift with all oral Therapies Mamta K. Jain, M.D., M.P.H. UT Southwestern Medical Center Financial Disclosure Research Grants: Gilead Sciences AbbVie Pharmaceuticals Merck
More informationProfessor David Back
THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor David Back University of Liverpool 1-4 April 2014, Arena and Convention Centre Liverpool THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor
More informationHIV-HCV Co-Infection. George Mason University Falls Church, Virginia. Overview. Prevalence of HCV co-infection Incidence and Recent Trends
HIV-HCV Co-Infection Zobair Younossi MD, MPH, FACG, AGAF, FAASLD Chairman, Department of Medicine, Inova Fairfax Hospital Vice President for Research, Inova Health System Professor of Medicine, VCU-Inova
More informationUpdate on the Treatment of HCV
Update on the Treatment of HCV K. Rajender Reddy, MD Professor of Medicine Director of Hepatology Director, Viral Hepatitis Center University of Pennsylvania Philadelphia, USA 1 K. Rajender Reddy, MD Disclosure
More informationConsiderations for the management of Hepatitis C in patients with HIV co-infection
Considerations for the management of Hepatitis C in patients with HIV co-infection Marcella Honkonen, PharmD, BCPS Sunday, February 22, 2012 at 10:15 AM AzPA Southwest Clinical Conference JW Marriott,
More informationHEPATITIS WEB STUDY. Treatment of Hepatitis C following Liver Transplantation
HEPATITIS WEB STUDY Treatment of Hepatitis C following Liver Transplantation Terry D. Box, MD Associate Professor of Medicine Division of Gastroenterology/Hepatology University of Utah Health Sciences
More information47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
More informationAddressing Unmet Medical Needs in HCV Genotype 3
Addressing Unmet Medical Needs in HCV Genotype 3 Karen Doucette, MD, MSc (Epi), FRCPC Associate Professor, Division of Infectious Diseases, Department of Medicine University of Alberta Objectives Identify
More informationHepatitis C in Special Populations
Hepatitis C in Special Populations David E. Bernstein, MD, FACG Vice Chairman of Medicine for Clinical Trials Chief, Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases Northwell Health
More informationGenotype 1 HCV in 2016: Clinical Decision Making in a Time of Plenty
Genotype 1 HCV in 216: Clinical Decision Making in a Time of Plenty Ira M. Jacobson, MD Chair, Department of Medicine Mount Sinai Beth Israel Senior Faculty and Vice-Chair, Department of Medicine Icahn
More informationHIV and Hepatitis C: Advances in Treatment
NORTHWEST AIDS EDUCATION AND TRAINING CENTER HIV and Hepatitis C: Advances in Treatment John Scott, MD, MSc Asst Professor University of Washington Presentation prepared & presented by: John Scott, MD,
More informationIFN-free therapy in naïve HCV GT1 patients
IFN-free therapy in naïve HCV GT1 patients Paris Hepatitis Conference Paris, 12th January, 2015 Pr Tarik Asselah MD, PhD; Service d Hépatologie & INSERM U773 University Paris Diderot, Hôpital Beaujon,
More informationCase 2: A 71-year-old man with cirrhosis
Case 2: A 71-year-old man with cirrhosis 1 JM, 71 year old African American male with known cirrhosis Asymptomatic apart from fatigue No prior history of decompensation Past history: Diabetes for 11 years
More informationNEXT GENERATION DIRECT-ACTING ANTIVIRALS
EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR IN PATIENTS CO-INFECTED WITH HEPATITIS C VIRUS AND HUMAN IMMUNODEFICIENCY VIRUS-1: THE EXPEDITION-2 STUDY J. Rockstroh, K. Lacombe, R. Viani, C. Orkin, D.
More informationCurrent State of Treatment for HCV. Nancy Reau, MD Associate Professor of Medicine University of Chicago
Activity Code FA376 Current State of Treatment for HCV Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives Upon completion of this presentation, learners should be
More informationAntiretroviral Therapy: What to Start
FLOWED: 05-14-2015 Chicago, IL: May 18, 2015 Antiretroviral Therapy: What to Start Eric S. Daar, MD Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles,
More informationSwitching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More information10/21/2016. Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina. Learning Objectives
A Crash Course on the AASLD/IDSA Hepatitis C Virus Infection Treatment Guidelines: What s New Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina FORMATTED: 1/3/16
More informationApproved regimens for cirrhotic patients
5th Workshop on HCV THERAPY ADVANCES New antivirals in clinical practice Approved regimens for cirrhotic patients Amsterdam, 4-5 december 2015 Disease burden in Spain 400000 350000 300000 F0 Peak cirrhosis
More informationGUIDELINES FOR INCORPORATING HIV/HCV PREVENTION INTO MEDICAL CARE
GUIDELINES FOR INCORPORATING HIV/HCV PREVENTION INTO MEDICAL CARE JOHN I. MCNEIL, MD, FACP MAXIMED ASSOCIATES MARYLAND JANUARY 25, 2018 CME Disclosures: Planning Committee And Speaker Speaker: The following
More informationAntiviral treatment in HCV cirrhotic patients on waiting list
Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory
More informationPhysiologically-Based Simulation of Daclatasvir Pharmacokinetics With Antiretroviral Inducers and Inhibitors of Cytochrome P450 and Drug Transporters
Physiologically-Based Simulation of Daclatasvir Pharmacokinetics With Antiretroviral Inducers and Inhibitors of Cytochrome P450 and Drug Transporters Qi Wang, Wenying Li, Ming Zheng, Timothy Eley, Frank
More informationTreating Hepatitis C Virus (HCV) Infection
Slide 1 of 42 Treating Hepatitis C Virus (HCV) Infection Susanna Naggie, MD, MHS Associate Professor of Medicine Duke Clinical Research Institute Durham, North Carolina Slide 3 of 42 Learning Objectives
More informationTreatments of Genotype 2, 3,and 4: Now and in the future
Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy
More informationHIV and Hepatitis C Have we finally slayed the beast?
HIV and Hepatitis C Have we finally slayed the beast? Mark W. Sonderup Division of Hepatology Department of Medicine University of Cape Town & Groote Schuur Hospital Accelerated Fibrosis in HIV-HCV co-infected
More informationKeynote Lecture: Optimal Management of HCV-HIV Coinfection
THASL Annual Meeting 2015 Keynote Lecture: Optimal Management of HCV-HIV Coinfection 26 February 2015 Prof. Chutima Pramoolsiansap Today s Talk HIV/HCV-coinfection Background and epidemiology When to start
More information